Company intelligence / Profile preview

Alpine Advisors

Seattle, Washington, United Statesalpinecpa.org ↗

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Povetacicept showed a 64.1% reduction in proteinuria for patients with IgA nephropathy in a Phase 1b/Phase 2a study. Additional trials ongoing/planned for lupus and autoimmune cytopenias.

Therapeutic areas: OncologyImmunologyNephrology
Modalities: Protein-based immunotherapyRecombinant proteinBiologicSmall molecule
Industry: Biotech

Partnerships

Kite Pharma ($535M deal/licensing agreement for two programs based on their technology)

Beyond the preview

Go deeper on Alpine Advisors.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpine Advisors.

Explore the full profile